Folschweiller, N., Vanden Abeele, C., Chu, L., Van Damme, P., García-Sastre, A., Krammer, F., Nachbagauer, R., Palese, P., Solórzano, A., Bi, D., David, M., Friel, D., Innis, B. L., Koch, J., Mallett, C. P., Rouxel, R. N., Salaun, B., Vantomme, V., Verheust, C., & Struyf, F. (2022). reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial. Lancet infectious diseases, 22(7), 1062–1075. http://access.bl.uk/ark:/81055/vdc_100158010598.0x00003f